Patient-Derived Gastric Cancer Assembloids: A New Benchmark in Tumor Microenvironment Modeling

Study Background and Research Question

Gastric cancer remains a major clinical challenge, being the fifth most diagnosed malignancy and the second leading cause of cancer-related deaths globally. Despite advances in surgical, chemotherapeutic, and targeted interventions, the five-year survival rate for patients with advanced or metastatic gastric cancer remains below 10%, largely due to tumor heterogeneity and variable treatment responses. Traditional in vitro models, including two-dimensional cultures and even more sophisticated three-dimensional organoids, often fail to replicate the complexity of the tumor microenvironment—particularly the influence of stromal cells such as fibroblasts, mesenchymal stem cells, and endothelial subsets. The primary research question addressed by Shapira-Netanelov et al. (2025) is whether integrating patient-matched stromal cell subpopulations with tumor organoids can yield an in vitro model that better recapitulates the biological and therapeutic complexity of human gastric cancer according to the reference study.

Key Innovation from the Reference Study

The central innovation is the creation of a patient-derived gastric cancer assembloid—a composite three-dimensional model that combines epithelial tumor organoids with stromal cell types directly isolated from the same primary tumor specimen. This approach moves beyond conventional organoid systems by incorporating the cellular heterogeneity and intercellular interactions that define the in vivo tumor niche. Notably, the inclusion of diverse stromal populations enables the assembloid to reflect not only the genetic but also the paracrine and matrix-mediated features of the patient’s tumor, addressing a critical gap in preclinical modeling.

Methods and Experimental Design Insights

The study’s methodology was rigorous and iterative. Researchers obtained tumor samples from gastric cancer patients and subjected them to mechanical and enzymatic dissociation. The resulting cell suspension was fractionated and expanded in media optimized for the growth of specific cell types: epithelial organoids, mesenchymal stem cells, fibroblasts, and endothelial cells. Each subpopulation was characterized phenotypically and genotypically to ensure fidelity to the patient’s original tumor tissue.

For assembloid generation, tumor organoids were co-cultured with one or more stromal cell types in an optimized medium that supported the viability and differentiation of all components. Immunofluorescence staining was used to assess biomarker expression, while RNA sequencing enabled high-resolution transcriptomic profiling. Drug responsiveness was evaluated through cell viability assays, including cell proliferation assays and cytotoxicity measurements, following exposure to various chemotherapeutic and targeted agents.

Protocol Parameters

• Tumor dissociation: Mechanical and enzymatic digestion of fresh gastric tumor tissue; optimize enzyme cocktail for maximal viable yield of both epithelial and stromal populations.
• Cell expansion: Use tailored growth media for each subpopulation (e.g., Wnt- and R-spondin-rich medium for organoids; FBS- and bFGF-supplemented medium for fibroblasts and mesenchymal cells).
• Co-culture conditions: Combine verified epithelial and stromal cells at ratios reflecting patient tissue composition; maintain in optimized assembloid medium to preserve phenotype.
• Biomarker analysis: Apply multiplex immunofluorescence panels targeting epithelial (e.g., EpCAM), stromal (e.g., vimentin, α-SMA), and endothelial (e.g., CD31) markers.
• Drug treatment: Administer therapeutic agents at concentrations relevant to clinical plasma levels; assess viability after 48–72 hours using luminescent cell viability assays or ATP-based readouts.
• Transcriptomic profiling: Isolate RNA from assembloids and perform next-generation sequencing to compare gene expression signatures between monocultures and co-cultures.

Core Findings and Why They Matter

The gastric cancer assembloids exhibited cellular heterogeneity and biomarker expression patterns closely matching primary patient tumors. Notably, assembloids displayed elevated expression of genes implicated in inflammatory signaling, extracellular matrix remodeling, and tumor progression when compared to monocultures of epithelial organoids. This enhanced physiological relevance translated into more nuanced drug response profiles: while certain drugs retained efficacy across both organoid and assembloid models, others lost potency in the presence of stromal subpopulations. This finding underscores the pivotal role of the tumor microenvironment in modulating therapeutic sensitivity and resistance as demonstrated in the reference study.

The model thus provides a platform for dissecting the mechanisms of antifolate drug resistance, testing protection from methotrexate-induced growth suppression, and evaluating combination therapy regimens in a context that mirrors patient-specific interactions. The ability to interrogate transcriptomic changes and biomarker modulation across different stromal compositions also facilitates the identification of novel predictive markers and resistance pathways.

Comparison with Existing Internal Articles

Several recent reviews and protocols have addressed the application of Leucovorin Calcium and related folate analogs in advanced cancer models. For instance, the article "Leucovorin Calcium: Precision in Folate Rescue for Complex Cancer Models" discusses how Leucovorin Calcium supports methotrexate rescue protocols and highlights its use in assembloid-based cell proliferation assays. Another review, "Leucovorin Calcium in Advanced Cancer Assembloid Research", details the methodological considerations for integrating folate metabolism pathway studies into assembloid workflows, emphasizing the importance of maintaining stromal and epithelial cell viability during antifolate challenge. These internal resources reinforce the relevance of the present study’s model for translational research, while the referenced article provides direct evidence of the assembloid system’s ability to capture patient-specific variability in drug response—a critical step forward.

Limitations and Transferability

Despite its strengths, the assembloid platform has inherent limitations. The co-culture system, while more representative than monocultures, cannot fully replicate the immune and vascular dynamics of in vivo tumors. Additionally, the generation of patient-specific assembloids is labor-intensive and may not be feasible at scale for all research settings. Differences in stromal cell isolation efficiency and heterogeneity across patient samples can impact reproducibility. Furthermore, drug screening in this model may not account for pharmacokinetic factors or interactions with non-tumor organ systems. Nevertheless, the system offers a robust preclinical testing ground for mechanistic studies and personalized therapy optimization.

Research Support Resources

To facilitate research into methotrexate resistance, folate metabolism, and cell rescue protocols within tumor assembloid models, investigators may employ reagents such as Leucovorin Calcium (SKU A2489), a high-purity calcium folinate suitable for protection from methotrexate-induced growth suppression and for use in cell proliferation assays. For optimal stability, researchers should prepare fresh solutions and store the solid form at -20°C, as detailed in the product documentation. Incorporating Leucovorin Calcium into assembloid-based workflows aligns with best practices described in recent methodological reviews, supporting reliable and reproducible outcomes in antifolate drug resistance research. For further guidance on workflow optimization, relevant protocols and discussions are available in the cited internal articles.